Early TIPS procedure versus standard care after a first complication of cirrhosis
Compares early TIPS with standard care in adults with cirrhosis after a first complication.
Plain-language title generated from the registry record
Registry title: "Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis
Key facts
- Where
- Besançon, Créteil, Lyon, Marseille, Nantes, Paris, Rennes, and Toulouse, FranceSee the 8 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07889726, who can take part
Where in France
- Hepatology Department - Besançon University HospitalBesançon, FranceNo longer taking part
- Hepatology Department - Henry Mondor HospitalCréteil, FranceNo longer taking part
- Hepatology Department - La Croix Rousse HospitalLyon, FranceNo longer taking part
- Hepatology Department - Saint Joseph HospitalMarseille, FranceNo longer taking part
- Hepatology Department - Hôtel DieuNantes, FranceNo longer taking part
- Hepatology Department - Pitié Salpétrière HospitalParis, FranceNo longer taking part
- Hepatology Department - Pontchaillou HospitalRennes, FranceNo longer taking part
- Hepatology Department - Toulouse University HospitalToulouse, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT07889726
- Record updated
- 22 October 2026
- Original description
Further decompensation (FD) in cirrhosis represents a prognostic stage associated with an even higher mortality than that associated with the first decompensation. The Baveno VII conference defined FD as a second portal hypertension (PH)-driven decompensating event (ascites, VB, or hepatic encephalopathy) and/or jaundice, or development of spontaneous bacterial peritonitis and/or hepatorenal syndrome-acute kidney injury HRS-AKI. This randomized controlled trial aims to evaluate the effect of TIPS versus standard of care on survival without further decompensation during a 24-month follow up period in patients with cirrhosis after a first PH-related decompensation.Read full original descriptionShow less
"Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis: a Multicenter, Superiority, Randomized, Controlled Trial, in Parallel Groups
Further decompensation (FD) in cirrhosis represents a prognostic stage associated with an even higher mortality than that associated with the first decompensation. The Baveno VII conference defined FD as a second portal hypertension (PH)-driven decompensating event (ascites, VB, or hepatic encephalopathy) and/or jaundice, or development of spontaneous bacterial peritonitis and/or hepatorenal syndrome-acute kidney injury HRS-AKI. This randomized controlled trial aims to evaluate the effect of TIPS versus standard of care on survival without further decompensation during a 24-month follow up period in patients with cirrhosis after a first PH-related decompensation.
Inclusion: Women and men,; 18 years < age ≤ 65 years,; With cirrhosis and a first PH-related complication defined as a first episode of variceal bleeding and/or a first episode of ascites requiring a paracentesis of > 2 liters (max 2 paracenteses),; Affiliated to a social insurance system,; Having signed the written informed consent to participate in the study; The diagnosis of cirrhosis will be based on Baveno VI conference.
Exclusion: Common contraindication for TIPS (MELD (Model for End stage Liver Disease) score > 18, Child Pugh score >11 (Appendix 7), Previous overt recurrent/chronic hepatic encephalopathy except during the index episode and High risk of post TIPS cardiac failure.); Previous liver transplantation; Previous derivation procedure; Patients with variceal bleeding and an indication of TIPS (salvage or pre-emptive TIPS); Untreated chronic viral B or C hepatitis; Uncontrolled systemic infection/sepsis; Patients with recurrent ascites (> 2 LVP); Hepatocellular carcinoma; Pregnant or breastfeeding women; Inability to receive an enlightened information; Patients participating to another research program; Patients placed under judicial protection; No ability for the participant to comply with the requirement of the study.